CTLT Stock Recent News
CTLT LATEST HEADLINES
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a spokesperson said on Monday.
Novo Holdings CEO Kasim Kutay discusses the surge in income from obesity drug sales and offers an update on the Catalent deal and insight on the company's deal strategy.
Novo Nordisk expects to close its acquisition of Catalent later this year, its chief financial officer said during the company's capital markets day on Thursday, adding that Novo's gross margin is seen falling in the coming years.
Catalent has reduced its headcount by about 300 employees as part of its ongoing restructuring plans, the company disclosed in a regulatory filing on Wednesday.
Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.
Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Catalent reported second-quarter revenue slightly above Wall Street estimates on Friday, days after the contract drug manufacturer agreed to a $16.5-billion acquisition offer from Novo Nordisk's parent firm.
Large bank stocks such as Berkshire Hathaway Inc. NYSE: BRK.B, JPMorgan Chase & Co. NYSE: JPM, and Citigroup Inc. NYSE: C are up in the past month as it's become clear that interest rates will remain high for the foreseeable future.
Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company's acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic. For more on this story, please see: https://www.bloomberg.com/news/articles/2024-02-05/novo-nordisk-spends-11-billion-on-meeting-obesity-drug-demand --------
The European Union's drugs regulator said on Wednesday it will investigate any risks to the availability of medicines processed at Catalent sites that will be sold to Novo Nordisk , part of its mandate to prevent drug shortages.